Yousif Capital Management LLC Sells 2,603 Shares of Bristol-Myers Squibb (NYSE:BMY)

Yousif Capital Management LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.1% during the 1st quarter, Holdings Channel reports. The fund owned 231,411 shares of the biopharmaceutical company’s stock after selling 2,603 shares during the quarter. Yousif Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $14,114,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealthspire Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock worth $1,622,000 after acquiring an additional 170 shares during the last quarter. Edmp Inc. increased its stake in shares of Bristol-Myers Squibb by 0.4% in the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company’s stock worth $2,353,000 after buying an additional 171 shares during the period. Bedel Financial Consulting Inc. increased its stake in shares of Bristol-Myers Squibb by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 175 shares during the period. King Wealth Management Group increased its stake in shares of Bristol-Myers Squibb by 2.6% in the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock worth $413,000 after buying an additional 182 shares during the period. Finally, Signet Investment Advisory Group Inc. increased its stake in shares of Bristol-Myers Squibb by 2.3% in the fourth quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 189 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY opened at $49.96 on Wednesday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market capitalization of $101.66 billion, a P/E ratio of -11.30, a P/E/G ratio of 2.07 and a beta of 0.38. The company’s 50-day simple moving average is $48.97 and its two-hundred day simple moving average is $54.92. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the prior year, the business earned ($4.40) EPS. The business’s quarterly revenue was down 5.6% on a year-over-year basis. As a group, analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 4,250 shares of the business’s stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.09% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BMY. Argus raised shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. UBS Group reduced their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Cantor Fitzgerald reissued a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.